Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2020-10-21 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2020年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled "普洛药业股份有限公司 2020 年第三季度报告正文" which translates to "Pu Luo Pharmaceutical Co., Ltd. 2020 Third Quarter Report Main Text." It contains detailed financial data for the third quarter of 2020, including key financial metrics, profit and loss statements, cash flow information, shareholder data, and management commentary on financial performance and business conditions. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (the third quarter) clearly indicates this is an Interim / Quarterly Report. The document length (8878 characters) and the detailed financial content confirm it is the report itself, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2020
2020-10-21 Chinese
关于药品临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of a clinical drug trial for 注射用索法地尔. It details the results of a Phase II clinical study, plans for Phase III, and safety and efficacy data. The document is relatively short (2796 characters) and focuses on clinical trial progress and related information rather than financial data or regulatory filings. It is not a financial report, earnings release, or management discussion. It is also not a regulatory filing or certification. The content is an update announcement about drug development progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial progress and risk disclosures, not a formal financial or governance report.
2020-10-14 Chinese
2020年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2020, providing estimated net profit and earnings per share for the period January 1 to September 30, 2020, and for the third quarter specifically. It explicitly states that the financial data is preliminary and unaudited, and that detailed financial data will be disclosed in the company's 2020 third quarter report. This type of document is a forward-looking earnings forecast rather than an actual earnings release or interim report containing substantive financial statements. It is a typical earnings guidance or earnings forecast announcement, which aligns with the category of Earnings Release (ER) as it provides initial announcement of quarterly/periodical financial results highlights, even though it is a forecast rather than final results. The document is short (941 characters) and contains key financial performance estimates, not just a notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the best classification is Earnings Release (ER). 9M 2020
2020-09-27 Chinese
关于受让下属公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's acquisition of 100% equity in a subsidiary company. It details the transaction overview, parties involved, financial data of the target company, and the purpose and impact of the transaction. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is focused on a capital transaction involving equity transfer within the corporate group. It is not a merger or acquisition announcement involving external parties, but rather an internal equity transfer. The document length is short (1685 characters), and it is a formal announcement of a capital/financing update related to shareholding changes within subsidiaries. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-09-24 Chinese
关于公司全资子公司购买的理财产品到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the maturity and redemption of financial products purchased by its wholly-owned subsidiary. It details the amounts, dates, and returns of these investments. The document is short (1268 characters) and primarily serves to inform shareholders and the public about the redemption event and related financial product details. It does not contain comprehensive financial statements, management discussion, or detailed financial results. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or officer attestation. The content fits best with a Capital/Financing Update as it relates to the company's use of idle funds for financial product investments and their redemption outcomes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-09-21 Chinese
关于投资设立上海普洛创智医药科技有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普洛药业股份有限公司 regarding its investment to establish a new subsidiary company, 上海普洛创智医药科技有限公司. It details the investment amount, ownership percentage, and strategic purpose of the investment. There is no financial report, earnings data, or regulatory certification present. The content focuses on a capital investment and company structure update. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising or capital structure changes through investment in a new entity.
2020-09-02 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.